Kevin Tang’s Concentra tries to disrupt proposed Acelyrin-Alumis merger

Con­cen­tra Bio­sciences, the shell com­pa­ny from Tang Cap­i­tal that tries to buy out strug­gling biotechs, has found an­oth­er tar­get, this time try­ing to throw a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.